fbpx

Psychedelic Medicine

Association

Psychedelic Medicine

Association

Excerpts from the publication

Background
Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms after only a single dose administration. Preclinical studies in animal models of addiction have provided proof-of-concept evidence in support of these claims. However, the purported therapeutic benefits of ibogaine are based on anecdotal reports from a small series of case reports that used retrospective recruitment procedures.

Methods
We reviewed clinical results from an open label case series (N = 191) of human volunteers seeking to detoxify from opioids or cocaine with medical monitoring during inpatient treatment. Whole blood was assayed to obtain pharmacokinetic measures to determine the metabolism and clearance of ibogaine. Clinical safety data and adverse events (AEs) were studied in male and female subjects. There were no significant adverse events following administration of ibogaine in a dose range that was shown to be effective for blocking opioid withdrawal symptoms in this study. We used multi-dimensional craving questionnaires during inpatient detoxification to test if ibogaine was effective in diminishing heroin and cocaine cravings. Participants also completed standardized questionnaires about their health and mood before and after ibogaine treatment, and at program discharge.

Results
One-month follow-up data were reviewed where available to determine if ibogaine’s effects on drug craving would persist outside of an inpatient setting. We report here that ibogaine therapy administered in a safe dose range diminishes opioid withdrawal symptoms and reduces drug cravings.

Conclusions
Pharmacological treatments for opioid dependence include detoxification, narcotic antagonists and long-term opioid maintenance therapy. Our results support product development of single oral dose administration of ibogaine for the treatment of opioid withdrawal during medically supervised detoxification to transition drug dependent individuals to abstinence.

Read more

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Robyn R. Jones, Marlene P. Freeman, Susan G. Kornstein, Kimberly Cooper, Ella J. Daly, Carla M. Canuso & Susan Nicholson
January 2022

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers

Juliana Mendes Rocha, Giordano Novak Rossi, Flávia L. Osório, José Carlos Bouso Saiz, Gabriela De Oliveira Silveira, Mauricio Yonamine, Eduardo José Crevelin, Maria Eugênia Queiroz, Jaime E. Cecílio Hallak and Rafael Guimarães Dos Santos
August 2021

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans

Miaoying Shi, Sebastiaan Wesseling, Hans Bouwmeester and Ivonne M. C. M. Rietjens
July 2021

Serotonin toxicity of serotonergic psychedelics

Benjamin Malcolm, Kelan Thomas
July 2021